Cargando…
Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088576/ http://dx.doi.org/10.1186/cc6426 |
| _version_ | 1782324978891358208 |
|---|---|
| author | Dhainaut, J Antonelli, M Wright, P Belger, M Cobas-Meyer, M Mignini, M Janes, J |
| author_facet | Dhainaut, J Antonelli, M Wright, P Belger, M Cobas-Meyer, M Mignini, M Janes, J |
| author_sort | Dhainaut, J |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4088576 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2008 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-40885762014-07-11 Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated) Dhainaut, J Antonelli, M Wright, P Belger, M Cobas-Meyer, M Mignini, M Janes, J Crit Care Poster Presentation BioMed Central 2008 2008-03-13 /pmc/articles/PMC4088576/ http://dx.doi.org/10.1186/cc6426 Text en Copyright © 2008 BioMed Central Ltd |
| spellingShingle | Poster Presentation Dhainaut, J Antonelli, M Wright, P Belger, M Cobas-Meyer, M Mignini, M Janes, J Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated) |
| title | Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated) |
| title_full | Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated) |
| title_fullStr | Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated) |
| title_full_unstemmed | Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated) |
| title_short | Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated) |
| title_sort | extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated) |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088576/ http://dx.doi.org/10.1186/cc6426 |
| work_keys_str_mv | AT dhainautj extendeddrotrecoginalfaactivatedtherapyinpatientswithpersistentrequirementforvasopressorsupportafter96hourinfusionwithcommercialdrotrecoginalfaactivated AT antonellim extendeddrotrecoginalfaactivatedtherapyinpatientswithpersistentrequirementforvasopressorsupportafter96hourinfusionwithcommercialdrotrecoginalfaactivated AT wrightp extendeddrotrecoginalfaactivatedtherapyinpatientswithpersistentrequirementforvasopressorsupportafter96hourinfusionwithcommercialdrotrecoginalfaactivated AT belgerm extendeddrotrecoginalfaactivatedtherapyinpatientswithpersistentrequirementforvasopressorsupportafter96hourinfusionwithcommercialdrotrecoginalfaactivated AT cobasmeyerm extendeddrotrecoginalfaactivatedtherapyinpatientswithpersistentrequirementforvasopressorsupportafter96hourinfusionwithcommercialdrotrecoginalfaactivated AT migninim extendeddrotrecoginalfaactivatedtherapyinpatientswithpersistentrequirementforvasopressorsupportafter96hourinfusionwithcommercialdrotrecoginalfaactivated AT janesj extendeddrotrecoginalfaactivatedtherapyinpatientswithpersistentrequirementforvasopressorsupportafter96hourinfusionwithcommercialdrotrecoginalfaactivated |